Implantable PAH drug pump study halted, ongoing support for patients

NCT ID NCT01321073

First seen Jan 30, 2026 · Last updated May 23, 2026 · Updated 16 times

Summary

This study looked at the safety of an implantable catheter and pump system that delivers a medication called Remodulin directly into the body for people with pulmonary arterial hypertension (PAH). The study enrolled 64 participants. Development of the system has stopped, but the study now provides continued support for the roughly 30 patients who still have the device implanted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AdventHealth Orlando

    Orlando, Florida, 32803, United States

  • Aurora St. Lukes Medical Center

    Milwaukee, Wisconsin, 53234, United States

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390-7208, United States

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California, 90073, United States

Conditions

Explore the condition pages connected to this study.